Expression of Transmembrane Glycoprotein TROP2 in Triple-Negative Breast Cancer and It’s Potential as a Molecular Classifier for Targeted Therapy
Trophoblast Cell-surface antigen 2 (TROP2), a calcium signal transducer & a transmembrane glycoprotein expression was studied in Triple-Negative Breast Cancer (TNBC) patients. mRNA expression, immunohistochemical and immunofluorescence analysis illustrated a higher TROP2 expression in the TNBC tissues. Assessment of tumor-infiltrating lymphocytes in TNBC samples was done and <i>in silico</i> studies depicted a significant association between TROP2 expression and infiltration of CD4+ cells. Kaplan-Meier survival analysis observed TROP2 expression to be an independent determinant of survival, with better survival benefit in the TROP2 high group. Our study paves the way for newer therapies targeting TROP2 for TNBC patients.
Authors
- N. Balasubramanian (ORCID: https://orcid.org/0000-0003-1819-0730)
- Vaishnavi Balasubramanian
- Ganesh Venkatraman (ORCID: https://orcid.org/0000-0003-0179-9785)
- Gouthaman Shanmugasundaram
- V Pavithra
- Suresh K. Rayala (ORCID: https://orcid.org/0000-0003-4394-4450)
- Bhawna Dev (ORCID: https://orcid.org/0000-0003-1771-9743)
- Sandhya Sundaram (ORCID: https://orcid.org/0000-0001-9878-4365)
- Roshni Saravanan
- Srikanth Swamy Swaroop B
- J Naidu
- Ravi Shankar Pitani
Institutions
- Sri Ramachandra Institute of Higher Education and Research (IN)
- Indian Institute of Technology Madras (IN)
- Vellore Institute of Technology University (IN)
Publication Details
- Journal
- Cancer Investigation
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1080/07357907.2025.2595303
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00